Vitaliano, Gordana D. http://orcid.org/0000-0002-9371-3733
Kim, Jae K.
Kaufman, Marc J. http://orcid.org/0000-0002-4383-1264
Adam, Christopher W.
Zeballos, Gonzalo
Shanmugavadivu, Abinaya http://orcid.org/0000-0002-4998-5176
Subburaju, Sivan
McLaughlin, Jay P. http://orcid.org/0000-0001-9851-9342
Lukas, Scott E.
Vitaliano, Franco
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R44MH10848)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (R44DA044050, K08DA037465, T32DA015036, R01DA039044)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse
Article History
Received: 29 October 2020
Accepted: 17 February 2022
First Online: 17 March 2022
Competing interests
: F.V. is an employee of ExQor Technologies, Inc. G.V. and F.V. own equity in ExQor, the company that owns patent rights to the bioengineered clathrin protein nanotechnology (patents #7216038, #7219017, #7219018, #7393924, #13/847,058 and #12/399,906). G.V’s and F.V’s interests were reviewed and subject to a management plan overseen by McLean Hospital/Harvard University and Partners HealthCare in accordance with their conflict of interest policies. J.P.M. and S.S. were consultants on ExQor’s SBIR NIH grant # R44MH108481. M.J.K. receives royalties from and is an inventor on a patent assigned to the McLean Hospital Corporation covering the use of xenon gas, to treat post-traumatic stress disorder. He received payments for consultant/advisory services from the University of Mississippi, Theranano LLC, and System Analytic, and for grant review service from the Fund for Scientific Research, Belgium. The remaining authors declare no competing interests.